Avita Medical, Inc. (RCEL) Stock Price & Analysis
Avita Medical, Inc. (RCEL) fell 0.96% to USD 4.12 as of June 10, 2026 at 03:46 UTC, according to Nexqual real-time market data.
RCEL last closed at USD 4.16; the session ranged USD 3.95–4.21 on volume of 199,898 shares. Market capitalization is $126.80M, with a 52-week range of USD 3.22–7.12 (NCM). Source: Nexqual, June 10, 2026 at 03:46 UTC.
Key Statistics (as of June 10, 2026 at 03:46 UTC)
| Price | USD 4.12 |
|---|---|
| Change | ▼ 0.96% (down) |
| Previous Close | USD 4.16 |
| Open | USD 4.16 |
| Day Range | USD 3.95 – 4.21 |
| 52-Week Range | USD 3.22 – 7.12 |
| Volume | 199,898 shares |
| Market Cap | $126.80M |
| Exchange | NCM |
Technical Analysis (RCEL)
Nexqual's technical model rates RCEL "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:46 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.63 (neutral) |
| vs SMA50 | Below (USD 4.38) |
| MACD | -0.06 (negative) |
Analyst Ratings (RCEL)
Wall Street analysts rate RCEL "Strong Buy" based on 3 analysts, with a mean price target of USD 7.07 (range USD 5.35–9.95), per Nexqual as of June 10, 2026 at 03:46 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 7.07 |
| High Target | USD 9.95 |
| Low Target | USD 5.35 |
| Buy / Hold / Sell | 3 / 1 / 0 |
Earnings (RCEL)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.41 |
| Revenue Estimate | $27.82M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.48 vs est -0.38 ▼ miss |
| 2025-12-31 | USD -0.54 vs est -0.55 ▲ beat |
| 2025-09-30 | USD -0.71 vs est -0.45 ▼ miss |
| 2025-06-30 | USD -0.58 vs est -0.36 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Financials & Fundamentals (RCEL)
| Total Revenue | $72.35M |
|---|---|
| Revenue Growth (YoY) | +4.00% |
| Gross Margin | +81.36% |
| Operating Margin | -45.73% |
| Profit Margin | -62.67% |
| Current Ratio | 0.48 |
| Total Cash | $14.26M |
| Total Debt | $48.12M |
| Free Cash Flow | $-18.31M |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Financial Health Score (RCEL)
Nexqual rates Avita Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:46 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 81%, operating -46% |
| Balance Sheet | Mixed — $14M cash vs $48M debt |
| Cash Flow | Weak — FCF negative: -$18M, burning cash |
| Efficiency | Mixed — No data |
Ownership (RCEL)
| Insider Ownership | +1.11% |
|---|---|
| Institutional Ownership | +17.15% |
| Shares Outstanding | 30.78M |
| Float | 30.39M |
| Short % of Float | +10.83% |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
Leadership (RCEL)
Avita Medical, Inc. is led by Cary G. Vance (age 59), President, CEO & Executive Director, per Nexqual as of June 10, 2026 at 03:46 UTC.
| President, CEO & Executive Director | Cary G. Vance (age 59) |
|---|---|
| Chief Financial Officer | David O'Toole (age 66) |
| Senior Vice President of Global Operations | Niraj Doshi J.D., P.M.P. |
| Senior Vice President of Scientific & Medical Affairs | Katie Bush |
| Vice President of Investor Relations & Corporate Communications | Ben Atkins |
Major Backers & Investors (RCEL)
Notable institutional backers of Avita Medical, Inc. include Fidelity, Morgan Stanley, Divisadero Street Capital Management, LP, according to Nexqual as of June 10, 2026 at 03:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.25% |
| Morgan Stanley | 0.51% |
| Divisadero Street Capital Management, LP | 0.32% |
| Goldman Sachs | 0.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.39% |
| BlackRock | 5.21% |
| Geode Capital | 1.76% |
| State Street | 1.39% |
| Northern Trust | 0.6% |
Source: Nexqual, June 10, 2026 at 03:46 UTC.
From Avita Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- RECELL (including RECELL GO) has received CE-mark approval in Europe; RECELL, excluding RECELL GO, has received PMDA approval for burns in Japan and is TGA-registered in Australia.   HEALTHCARE LAWS AND REGULATIONS AVITA Medical is a manufacturer of medical devices, and therefore we are subject to regulations by the FDA and various federal and state healthcare laws and regulations.
- Our commercial success also depends in part on our ability to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights.
- This indication materially expands our addressable market and allows us to leverage our existing commercial infrastructure and clinical relationships.
Partnerships
- In July 2024, we entered into an exclusive multi-year development and distribution agreement with Collagen Matrix, LLC d/b/a as Regenity Biosciences ("Regenity"), granting us exclusive rights to market, sell, and distribute Cohealyx, an AVITA-medical branded collagen-based dermal matrix in the U.S., with potential expansion into the European Union ("E.U."), Australia, and Japan.
- In January 2024, we entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. ("Stedical") to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix in the United States ("U.S.").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SIBN | SI-BONE, Inc. | USD 15.53 | ▲ 2.71% |
| TELA | TELA Bio, Inc. | USD 0.94 | ▲ 6.25% |
| ORIC | Oric Pharmaceuticals, Inc. | USD 8 | ▲ 6.67% |
| PROF | Profound Medical Corp. | USD 6.82 | ▲ 2.4% |
| LUNG | Pulmonx Corporation | USD 1.53 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:46 UTC. This page is informational and not investment advice.